{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:50:58Z","timestamp":1774875058611,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pisa syndrome (PS) is characterized by an abnormally sustained posture, with flexion of the body and head to one side and slight rotation of the trunk. Although PS most commonly arises as an adverse effect of antipsychotic drugs, choline-esterase inhibitors (ChEIs) are also sometimes known to induce PS. Despite the fact that the precise mechanism remains unclear, cholinergic-dopaminergic imbalance has been considered as a possible pathophysiologic mechanism underlying the genesis of PS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We hereby report the case of a 60-year-old woman with Alzheimer\u2019s disease who presented with the signs of PS after her treatment was switched to galantamine, a type of ChEI, even though she had received donepezil, another type of ChEI, for 5\u2009years without any complications. To the best of our knowledge, this is the first report of PS associated with treatment switch from one to another type of ChEI. Galantamine, but not other ChEIs, can enhance striatal dopamine release through allosteric modulation of the nicotinic acetylcholine receptor, and has weaker muscarinic effects than donepezil. Therefore, we propose two novel hypotheses to explain the development of PS, as follows; galantamine, which enhances dopamine release, can induce imbalance of dopamine levels in the striatum of patients with dementia, resulting in PS, and the weaker muscarinic effects of the drug could be one of the factors predisposing to the development of PS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The present case suggests that treatment with galantamine is associated with a higher risk of development of PS than that with other ChEIs, such as donepezil, despite the pharmacological profile of galantamine as a dopamine modulator. Also, this report provides novel insight into another plausible mechanism underlying the development of PS, besides cholinergic-dopaminergic imbalance, namely, dopamine imbalance in the striatum with muscarinic-nicotinic imbalance.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-020-01769-2","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T09:19:35Z","timestamp":1589361575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-6785","authenticated-orcid":false,"given":"Yu","family":"Mimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Funayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1474-4422(11)70067-9","volume":"10","author":"KM Doherty","year":"2011","unstructured":"Doherty KM, Van De Warrenburg BP, Peralta MC, Silveira-moriyama L, Azulay J, Gershanik OS. Postural deformities in Parkinson\u2019s disease. Lancet Neurol. 2011;10:538\u201349.","journal-title":"Lancet Neurol"},{"key":"1769_CR2","first-page":"94","volume":"202","author":"K Ekbom","year":"1972","unstructured":"Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972;202:94\u2013103.","journal-title":"Z Neurol"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/00023210-200216030-00003","volume":"16","author":"T Suzuki","year":"2002","unstructured":"Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (Pleurothotonus). CNS Drugs. 2002;16:165\u201374.","journal-title":"CNS Drugs"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(00)02412-0","volume":"355","author":"YT Kwak","year":"2000","unstructured":"Kwak YT, Han IIW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet. 2000;355:2222.","journal-title":"Lancet."},{"key":"1769_CR5","doi-asserted-by":"crossref","unstructured":"Chen CF, Hsu HC, Ouyang WC, Lin YC. Galantamine-induced pisa syndrome: Memantine as an alternative. Int J Geriatr Psychiatry. 2008;23:660\u20131.","DOI":"10.1002\/gps.2021"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1600-0404.2005.00388.x","volume":"111","author":"N Vanacore","year":"2005","unstructured":"Vanacore N, Suzzareddu G, Maggini M, Casula A, Capelli P, Raschetti R. Pisa syndrome in a cohort of Alzheimer\u2019s disease patients. Acta Neurol Scand. 2005;111:199\u2013201.","journal-title":"Acta Neurol Scand"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/0004867417741983","volume":"52","author":"PC Chao","year":"2018","unstructured":"Chao PC, Li JC, Yeh TC, Bin YC. A very low dose of rivastigmine-induced Pisa syndrome in a clozapine-treated patient. Aust N Z J Psychiatry. 2018;52:204\u20135.","journal-title":"Aust N Z J Psychiatry"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/WNF.0000000000000215","volume":"40","author":"CW Hsu","year":"2017","unstructured":"Hsu CW, Lee Y, Lee CY, Lin PY. Reversible Pisa syndrome induced by rivastigmine in a patient with early-onset Alzheimer disease. Clin Neuropharmacol. 2017;40:147\u20138.","journal-title":"Clin Neuropharmacol"},{"key":"1769_CR9","first-page":"529","volume":"46","author":"D Pollock","year":"2017","unstructured":"Pollock D, Cunningham E, Mcguinness B, Passmore AP. Pisa syndrome due to donepezil: pharmacokinetic interactions to blame? Age Ageing. 2017;46:529\u201330.","journal-title":"Age Ageing"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1176\/appi.neuropsych.11070158","volume":"24","author":"I Panagiotis","year":"2012","unstructured":"Panagiotis I, Pantelis M, George B, Dimitris K. Acute Pisa syndrome after administration of a single dose of donepezil. J Neuropsychiatry Clin Neurosci. 2012;24:2012.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1440-1819.2011.02196.x","volume":"65","author":"M Shinfuku","year":"2011","unstructured":"Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, Kashima H. Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2011;65:299.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/mds.20164","volume":"19","author":"G Cossu","year":"2004","unstructured":"Cossu G, Melis M, Melis G, Maccioni E, Putzu V, Catte O, et al. Reversible Pisa syndrome (Pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. Mov Disord. 2004;19:1243\u20134.","journal-title":"Mov Disord"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4088\/JCP.v62n07d13","volume":"62","author":"T Miyaoka","year":"2001","unstructured":"Miyaoka T, Seno H, Yamamori C, Inagaki T, Itoga M, Tsubouchi KHJ. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry. 2001;62:573\u20134.","journal-title":"J Clin Psychiatry"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00002826-200305000-00004","volume":"26","author":"A Villarejo","year":"2003","unstructured":"Villarejo A, Camacho A, Garcia-Ramos R, Moreno T, Penas M, Juntas R, et al. Case report: cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol. 2003;26:119\u201321.","journal-title":"Clin Neuropharmacol"},{"key":"1769_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/j.1532-5415.2007.01283.x","volume":"55","author":"D Huvent-Grelle","year":"2007","unstructured":"Huvent-Grelle D, Roche J, Camus FE, Dewailly PH, Puisieux F. Relation between cholinesterase inhibitors and Pisa syndrome in a cohort of five French patients with Alzheimer\u2019s disease. JAGS. 2007;55:1472\u201387.","journal-title":"JAGS."},{"issue":"1","key":"1769_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lpm.2008.08.007","volume":"38","author":"D Huvent-Grelle","year":"2009","unstructured":"Huvent-Grelle D, Roche J, Gaxatte C, Dewailly P, Puisieux F. Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients. Presse Med. 2009;38(1):150\u20133.","journal-title":"Presse Med"},{"key":"1769_CR17","first-page":"31","volume":"163","author":"M Leelavathi","year":"2012","unstructured":"Leelavathi M, Rosdinom R, Suguna M. Pisa syndrome secondary to rivastigmine: a case report. Clin Ter. 2012;163:31\u20132.","journal-title":"Clin Ter"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajp.2018.05.003","volume":"35","author":"SSR Mukku","year":"2018","unstructured":"Mukku SSR, Achary U, Sivakumar PT, Varghese M. Reccurent truncal dystonia (Pisa syndrome) due to donepezil \u2014 A case report. Asian J Psychiatr. 2018;35:47\u20139.","journal-title":"Asian J Psychiatr"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4103\/psychiatry.IndianJPsychiatry_308_16","volume":"59","author":"RNS Kumar","year":"2017","unstructured":"Kumar RNS, \ufeffGopalakrishnan A. Clozapine-associated Pisa syndrome: a rare type of tardive dystonia. Indian J Psychiatry 2017; 59: 390\u2013391.","journal-title":"Indian J Psychiatry"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jspd.2015.02.003","volume":"3","author":"F Faridhosseini","year":"2015","unstructured":"Faridhosseini F, Omidi-Kashani F, Baradaran A. Pisa syndrome associated with clozapine: a rare case report and literature review. Spine Deform. 2015;3:386\u20139.","journal-title":"Spine Deform"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/0006-3223(91)90061-P","volume":"29","author":"R Yassa","year":"1991","unstructured":"Yassa R, Nastase C, Cvejic J, Laberge G. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry. 1991;29:942\u20135.","journal-title":"Biol Psychiatry"},{"key":"1769_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40360-018-0272-8","volume":"19","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Takano H, Yamada M, Satake N, Hirabayashi N, Okazaki M, et al. Pisa syndrome associated with mirtazapine: a case report. BMC Pharmacol Toxicol. 2018;19:18\u201320.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1176\/appi.neuropsych.11070165","volume":"24","author":"V Perrone","year":"2012","unstructured":"Perrone V, Antoniazzi S, Carnovale C, Clementi E, Radice S, Ba G, et al. A case of Pisa syndrome during sertraline and Quetiapine treatment. J Neuropsychiatry Clin Neurosci. 2012;24:31\u20132.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1212\/WNL.0000000000003892","volume":"88","author":"N Kumar","year":"2017","unstructured":"Kumar N, Mendon\u00e7a DA, Jog M. Teaching video Neuro images: Lithium-induced reversible Pisa syndrome. Neurology. 2017;88:e184.","journal-title":"Neurology."},{"key":"1769_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1176\/appi.ajp.163.2.325-a","volume":"163","author":"M Yohanan","year":"2006","unstructured":"Yohanan M, Aulakh JS, Weith J, Hawkins JW. Pisa syndrome in a patient in a wheelchair taking Valproic acid. Am J Psychiatry. 2006;163:325.","journal-title":"Am J Psychiatry"},{"key":"1769_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/jnnp.38.8.787","volume":"38","author":"RC Duvoisin","year":"1975","unstructured":"Duvoisin RC, Marsden CD. Note on the scoliosis of parkinsonism. J Neurol Neurosurg Psychiatry. 1975;38:787\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382\u20139.","journal-title":"Arch Neurol"},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/phar.1359","volume":"34","author":"AS Zannas","year":"2014","unstructured":"Zannas AS, Okuno Y, Doraiswamy PM. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. Pharmacotherapy. 2014;34:272\u20138.","journal-title":"Pharmacotherapy."},{"key":"1769_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuint.2016.02.008","volume":"94","author":"M Inden","year":"2016","unstructured":"Inden M, Takata K, Yanagisawa D, Ashihara E, Tooyama I, Shimohama S, et al. \u03914 nicotinic acetylcholine receptor modulated by Galantamine on Nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior. Neurochem Int. 2016;94:74\u201381.","journal-title":"Neurochem Int"},{"key":"1769_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jphs.2015.03.004","volume":"127","author":"S Shimizu","year":"2015","unstructured":"Shimizu S, Mizuguchi Y, Sobue A, Fujiwara M, Morimoto T, Ohno Y. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. J Pharmacol Sci. 2015;127:439\u201345.","journal-title":"J Pharmacol Sci"},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/syn.20969","volume":"65","author":"Y Ago","year":"2011","unstructured":"Ago Y, Koda K, Ota Y, Kita Y, Fukada A, Takuma K, et al. Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses. Synapse. 2011;65:1373\u20137.","journal-title":"Synapse."},{"key":"1769_CR32","first-page":"1","volume":"10 SEP","author":"Y Ohno","year":"2019","unstructured":"Ohno Y, Kunisawa N, Shimizu S. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): Management of extrapyramidal side effects. Front Pharmacol. 2019;10 SEP:1\u201310.","journal-title":"Front Pharmacol"},{"key":"1769_CR33","doi-asserted-by":"crossref","unstructured":"Vi tale C, Falco F, Trojano L, Erro R, Moccia M, Allocca R, et al. Neuropsychological correlates of Pisa syndrome in patients with Parkinson\u2019s disease. Acta Neurol Scand. 2016;101\u20137.","DOI":"10.1111\/ane.12514"},{"key":"1769_CR34","first-page":"1","volume-title":"Pisa Syndrome in Parkinson\u2019s Disease Is Associated with Specific Cognitive Alterations","author":"CA Artusi","year":"2019","unstructured":"Artusi CA, Montanaro E, Tuttobene S, Romagnolo A, Zibetti M, Lopiano L. Pisa Syndrome in Parkinson\u2019s Disease Is Associated with Specific Cognitive Alterations; 2019. p. 1\u20137."},{"key":"1769_CR35","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2018-0052","volume-title":"Diagnostic evaluation and monitoring of patients with posterior cortical atrophy","author":"B Wong","year":"2019","unstructured":"Wong B, Lucente DE, Maclean J, Padmanabhan J, Brandt KD, Putcha D, et al. Diagnostic evaluation and monitoring of patients with posterior cortical atrophy. 2019; December 2018."},{"key":"1769_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01769-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T23:14:46Z","timestamp":1620861286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01769-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01769-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"3 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from family member of the patient for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}